![]() |
市場調查報告書
商品編碼
1625232
至 2030 年 Beta 伏打電池設備市場預測:按同位素類型、設備配置、應用、最終用戶和地區進行的全球分析Betavoltaic Device Market Forecasts to 2030 - Global Analysis By Isotope Type (Tritium (H-3), Nickel-63, Promethium-147 and Other Radioisotopes), Device Configuration, Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,2024 年全球 beta voltaic 裝置市場規模為 2.047 億美元,預計預測期內複合年成長率為 12.8%,到 2030 年將達到 4.217 億美元。
貝塔伏特裝置,也稱為貝塔伏特電池或電池,利用放射性同位素發射的貝塔粒子來發電。這些設備的工作原理是BETA崩壞,其中高能量電子與半導體材料相互作用產生電流。 Beta 伏特裝置以其長達數十年的長使用壽命而聞名,用於需要可靠、免維護電源的應用,例如醫療植入、遠端感測器和太空技術。其緊湊的設計和耐用性使其成為惡劣或難以進入的環境的理想選擇。
根據《應用物理學雜誌》報導,貝塔伏特裝置已證明能夠在超過 733K(460°C;860°F)的高溫環境中運作。
可長時間供電
Betavolta 設備提供長壽命電源,其使用壽命通常長達數十年。如此長的使用壽命非常適合無法定期維護或更換電池的偏遠地區或惡劣環境中的應用,例如太空任務、水下感測器和醫療植入。無需充電即可提供持續電力的能力使其在可靠性和耐用性非常重要的航太和醫療保健等多個領域具有吸引力。
開發成本高
高開發成本是貝塔伏特元件市場的主要限制因素。這些成本是由複雜的製造流程以及安全處理放射性同位素所需的專門材料和技術造成的。此外,嚴格的安全和環境合規監管要求也增加了經濟負擔。這些因素可能會限制新參與企業的市場進入,減緩技術創新的步伐,並阻礙貝塔伏特設備的廣泛採用。
技術進步
科技的進步為太陽能電池市場帶來了巨大的機會。材料科學和半導體技術的創新正在提高設備的效率和功率。這些進步正在提高貝塔伏特設備在更廣泛應用中的實用性,包括物聯網設備和先進的醫療植入。隨著改善能源轉換過程和降低生產成本的研究不斷取得進展,市場有望擴展到需要可靠、長期電力解決方案的新領域。
放射性同位素的供應有限
放射性同位素的有限供應對貝塔伏特設備市場構成了威脅。氚等放射性同位素對於這些設備至關重要,但供應量並不豐富,這可能會導致供應鏈限制和成本增加。這種稀缺性可能會促使製造商尋求替代材料和技術,從而將投資從BETA太陽能電池解決方案上轉移出去。
由於供應鏈中斷和原料短缺,COVID-19 大流行擾亂了 BETA 電壓元件市場。封鎖措施減緩了生產活動,並導致產品開發和部署的延遲。然而,隨著經濟復甦和監管放鬆,隨著關鍵應用中對可靠電源解決方案的需求增加,市場預計將復甦。
氚 (H-3) 領域預計將在預測期內成為最大的領域
由於氚 (H-3) 領域作為 BETA 伏打設備發電的 BETA 輻射源的有效性,預計在預測期內將佔據最大的市場佔有率。氚的半衰期長,因此可以長時間提供穩定的電力而無需維護。由於與其他同位素相比,它們很容易獲得且相對便宜,因此它們是需要耐用電源的應用的首選,例如醫療植入和遠端感測器。
醫療植入領域預計在預測期內複合年成長率最高。
在預測期內,由於醫療保健領域對持久電源解決方案的需求不斷增加,醫療植入產業預計將出現最高的複合年成長率。 Betavolta 設備在為心律調節器等植入植入供電、消除頻繁更換電池以及減少手術干預方面具有顯著優勢。慢性病的盛行率不斷上升,需要可靠的能源來源,透過確保設備的連續功能來增強患者護理,從而推動該領域的成長。
由於先進的技術基礎設施以及在國防和醫療保健領域的大量投資,預計北美地區將在預測期內佔據最大的市場佔有率。主要產業參與者的存在和持續的研究舉措進一步推動了市場的成長。該地區專注於開發創新電源解決方案,以滿足航太和醫療設備等關鍵應用對可靠能源來源的需求。
由於快速工業化和對可再生能源技術投資的增加,預計亞太地區在預測期內將實現最高成長率。中國、日本和韓國等國家正在各行業擴大使用緊湊、可靠的電源。該地區對技術進步的承諾支持了 beta-voltaic 設備市場的強勁成長軌跡。
According to Stratistics MRC, the Global Betavoltaic Device Market is accounted for $204.7 million in 2024 and is expected to reach $421.7 million by 2030 growing at a CAGR of 12.8% during the forecast period. A betavoltaic device, also known as a betavoltaic cell or battery, generates electricity using beta particles emitted by radioactive isotopes. These devices operate on the principle of beta decay, where energetic electrons interact with a semiconductor material, creating an electric current. Known for their long operational life, often spanning decades, betavoltaic devices are used in applications requiring reliable, maintenance-free power, such as medical implants, remote sensors, and space technology. Their compact design and durability make them ideal for harsh or inaccessible environments.
According to the Journal of Applied Physics, betavoltaic devices have demonstrated the ability to operate in high-temperature environments exceeding 733 K (460 °C; 860 °F).
Offers long-lasting power supply
Betavoltaic devices provide a long-lasting power supply, often lasting several decades, which is a significant driver for their market. This longevity makes them ideal for applications in remote or harsh environments where regular maintenance or battery replacement is impractical, such as in space missions, underwater sensors, and medical implants. Their ability to deliver continuous power without recharging enhances their appeal across various sectors, including aerospace and healthcare, where reliability and durability are critical.
High development costs
High development costs are a major restraint for the betavoltaic device market. These costs stem from the complex manufacturing processes and the need for specialized materials and technology to safely handle radioactive isotopes. Additionally, stringent regulatory requirements for safety and environmental compliance add to the financial burden. These factors can limit market entry for new players and slow down the pace of innovation, potentially hindering the widespread adoption of betavoltaic devices.
Advancements in technology
Advancements in technology present significant opportunities for the betavoltaic device market. Innovations in materials science and semiconductor technology are enhancing the efficiency and power output of these devices. Such advancements make betavoltaic devices more viable for a broader range of applications, including IoT devices and advanced medical implants. As research continues to improve energy conversion processes and reduce production costs, the market is poised for expansion into new sectors requiring reliable, long-term power solutions.
Limited availability of radioactive isotopes
The limited availability of radioactive isotopes poses a threat to the betavoltaic device market. Isotopes like tritium are crucial for these devices but are not abundantly available, which can lead to supply chain constraints and increased costs. This scarcity may drive manufacturers to seek alternative materials or technologies, potentially diverting investments away from betavoltaic solutions.
The Covid-19 pandemic disrupted the betavoltaic device market due to supply chain interruptions and raw material shortages. Lockdown measures slowed production activities, leading to delays in product development and deployment. However, as economies recover and restrictions ease, the market is expected to rebound with increased demand for reliable power solutions in critical applications.
The tritium (H-3) segment is expected to be the largest during the forecast period
The tritium (H-3) segment is expected to account for the largest market share during the forecast period due to its effectiveness as a beta radiation source for generating electricity in betavoltaic devices. Tritium's long half-life allows these devices to provide consistent power over extended periods without maintenance. Its availability and relatively low cost compared to other isotopes make it a preferred choice for applications requiring durable power sources, such as medical implants and remote sensors.
The medical implants segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the medical implants segment is expected to witness the highest CAGR due to increasing demand for long-lasting power solutions in healthcare. Betavoltaic devices offer significant advantages in powering implants like pacemakers, eliminating frequent battery replacements and reducing surgical interventions. The growing prevalence of chronic diseases necessitates reliable energy sources that enhance patient care by ensuring continuous device functionality, driving growth in this segment.
The North America region is anticipated to account for the largest market share during the forecast period due to its advanced technological infrastructure and significant investments in defense and healthcare sectors. The presence of key industry players and ongoing research initiatives further bolster market growth. The region's focus on developing innovative power solutions aligns with the demand for reliable energy sources in critical applications like aerospace and medical devices.
The Asia Pacific region is anticipated to register the highest growth rate over the forecast period driven by rapid industrialization and increasing investments in renewable energy technologies. Countries like China, Japan, and South Korea are expanding their use of compact and reliable power sources across various industries. The region's commitment to technological advancement supports its robust growth trajectory in the betavoltaic device market.
Key players in the market
Some of the key players in Betavoltaic Device Market include Widetronix, NDB, Inc., City Labs Inc., Qynergy Corporation, II-VI Incorporated, NorthStar Battery Co LLC, Exide Technologies, EaglePicher Technologies LLC, Curtiss-Wright Corporation, General Atomics, Thermo Fisher Scientific, Advent Technologies, Mouser Electronics, BetaBatt Inc., SHV Energy, Tech Etch Inc., H3 Battery LLC and Comsoll Inc.
In November 2024, City Labs has been awarded a Commercialization Readiness Pilot (CRP) from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. This significant funding will support the advancement of City Labs' innovative betavoltaic battery for leadless pacemakers, employing scalable fabrication techniques to prepare the technology for pre-clinical testing.
In July 2024, City Labs announced that it has been selected by AFWERX for a $1,250,000 Small Business Innovation Research (SBIR) Phase II contract. This award further supports the novel development of an advanced radioisotope-powered ion engine designed for small satellites. Building on the successful proof-of-concept City Labs established in the previously awarded Phase I contract, this Phase II effort aims to address critical propulsion challenges for the U.S. Department of the Air Force and lay the groundwork for producing a fully operational engine in the future that is capable of supporting missions lasting over five years.
In August 2020, NDB, Inc., creator of the first and only universal, self-charging, proprietary nano diamond battery (NDB) that provides up to thousands of years of charge announced completion of two successful Proofs of Concept tests of the NDB battery at Lawrence Livermore National Laboratory and the Cavendish Laboratory at Cambridge University. NDB's battery achieved a breakthrough 40% charge, a significant improvement over commercial diamonds, which have only 15% charge collection efficiency. NDB also announced its first two beta customers, including a leader in nuclear fuel cycle products and services and a leading global aerospace, defense and security manufacturing company.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.